Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 26.4B, Biogen(BIIB) trades at $179.89. The stock has a price-to-earnings ratio of 16.07.
As of 2026-01-30, Biogen(BIIB) stock has fluctuated between $176.00 and $180.14. The current price stands at $179.89, placing the stock +2.2% above today's low and -0.1% off the high.
The Biogen(BIIB)'s current trading volume is 1.47M, compared to an average daily volume of 1.31M.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $190.20 at its peak.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $190.20 at its peak.
BIIB News
If you are wondering whether Biogen's current share price offers good value or if you might be paying too much for its future potential, this article walks thro...
Oppenheimer analyst Jay Olson raised the firm’s price target on Biogen (BIIB) to $225 from $205 and keeps an Outperform rating on the shares. The firm says it i...
Bioge announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for litifilimab for the treatment of cutaneo...
Analyst ratings
51%
of 37 ratingsMore BIIB News
Eisai (ESAIY) and Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has accepted for review Eisai’s Supplemental Biologics License Applic...
Biogen (BIIB) is back in focus after the European Commission approved a high dose regimen of SPINRAZA for 5q spinal muscular atrophy. The decision expands the t...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.